Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics is a clinical-stage biopharmaceutical company with a promising discovery platform aiming to develop novel treatments for central nervous system disorders. Its lead candidate, ML-007C-MA, has shown potential in treating schizophrenia and Alzheimer's disease psychosis with reduced side effects. While there are competitive risks and uncertainties associated with trial outcomes, positive results could significantly impact the company's valuation.

Bears say

MapLight Therapeutics is currently in the clinical stage of drug development, and while its discovery platform shows potential for targeting specific neural circuits, the success of its product candidate, ML-007, is still uncertain in treating schizophrenia and ADP. Furthermore, with other potential treatments for these conditions also in development, MapLight faces competition in the market. Additionally, the article raises concerns about the company's ability to generate revenue, as it is currently focused on research rather than production. These factors combine to give a negative outlook on MapLight's stock.

MPLT has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 7 analysts, MPLT has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.